Cargando…
Successful weaning from mechanical ventilation in a patient with SMA type 1 treated with nusinersen
SMA type 1 is the most severe type, characterized by early onset at <6 months of age, and rapid progression resulting in permanent assisted ventilation before 2 years of life. Supportive care was the only treatment until the approval of nusinersen, an antisense oligonucleotide drug that increases...
Autores principales: | Lee, Jiwon, Park, Se Eun, Lee, Dajeong, Song, Joo Young, Lee, Jeehun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045896/ https://www.ncbi.nlm.nih.gov/pubmed/33616311 http://dx.doi.org/10.1002/acn3.51321 |
Ejemplares similares
-
NFL is a marker of treatment response in children with SMA treated with nusinersen
por: Olsson, Bob, et al.
Publicado: (2019) -
Successful weaning from the invasive respiratory support after nusinersen treatment in a child with SMA type 1: A case report
por: Pan, Meiling, et al.
Publicado: (2023) -
Quality of Life in SMA Patients Under Treatment With Nusinersen
por: Mix, Lucas, et al.
Publicado: (2021) -
Evaluator Training and Reliability for SMA Global Nusinersen Trials(1)
por: Glanzman, Allan M., et al.
Publicado: (2018) -
Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)